Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $9.8 million.

  • Taysha Gene Therapies' Current Deferred Revenue fell 53.39% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 53.39%. This contributed to the annual value of $9.8 million for FY2024, which is 45.87% down from last year.
  • As of FY2024, Taysha Gene Therapies' Current Deferred Revenue stood at $9.8 million, which was down 45.87% from $18.1 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Current Deferred Revenue ranged from a high of $33.6 million in FY2022 and a low of $9.8 million during FY2024.
  • Its 3-year average for Current Deferred Revenue is $20.5 million, with a median of $18.1 million in 2023.
  • Data for Taysha Gene Therapies' Current Deferred Revenue shows a maximum YoY tumbled of 46.04% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Taysha Gene Therapies' Current Deferred Revenue stood at $33.6 million in 2022, then crashed by 46.04% to $18.1 million in 2023, then crashed by 45.87% to $9.8 million in 2024.